Roche Holding Ltd · SIX:RO

Roche — AACR 2020

8 slides from Roche's conference presentation, 2020

  1. Slide 1: Phase Ib/II Evaluation of Atezolizumab + Cobimetinib in MORPHEUS-NSCLC, PDAC and GC

    Phase Ib/II Open-Label, Randomized Evaluation of Atezolizumab + Cobimetinib vs Control in MORPHEUS-NSCLC (Non-Small Cell Lung Cancer), MORPHEUS-PDAC (Pancreatic Ductal Adenocarcinoma) and MORPHEUS-GC (Gastric Cancer) Byoung Chul Cho,1 Nathan Bahary,2 Johanna Bendell,3 Enriqueta Felip,4 Melissa Johns

  2. Slide 2: Disclosures

    Disclosures  Research funding: Novartis, Bayer, AstraZeneca, MOGAM Institute, Dong-A ST, Champions Oncology, Janssen, Yuhan, Ono Pharmaceutical, Dizal Pharma, MSD  Consulting role: Novartis, AstraZeneca, Boehringer Ingelheim, Roche, BMS, Ono Pharmaceutical, Yuhan, Pfizer, Eli Lilly, Janssen, Taked

  3. Slide 3: MORPHEUS Platform and Study Design

    MORPHEUS Platform and Study Design  MORPHEUS is a Phase Ib umbrella platform that enables evaluation of multiple treatment combinations across a variety of tumors to rapidly generate evidence of transformative efficacy  Atezolizumab (anti–PD-L1) + cobimetinib (MEK1/MEK2 inhibitor) was evaluated in

  4. Slide 4: MORPHEUS Platform and Study Design

    MORPHEUS Platform and Study Design  MORPHEUS is a Phase Ib umbrella platform that enables evaluation of multiple treatment combinations across a variety of tumors to rapidly generate evidence of transformative efficacy  Atezolizumab (anti–PD-L1) + cobimetinib (MEK1/MEK2 inhibitor) was evaluated in

  5. Slide 5: Clinical Activity Summary

    Clinical Activity Summary PDAC (2L) PDAC (3L) NSCLC (2L/3L post CPI/plat chemo) GC (1L) CCOD Oct 14, 2019 CCOD Oct 14, 2019 CCOD Feb 14, 2020 CCOD July 11, 2019 Controla Atezo + Cobi Atezo + Cobib Atezo + Cobi Atezo + mFOLFOX6 + Controlc (n = 14) (n = 15) (n = 14) (n = 14) (n = 15) Cobi (n = 5) Conf

  6. Slide 6: Relationship Between PD-L1 Status, Tumor Immune Phenotype and Best Overall Response

    Relationship Between PD-L1 Status, Tumor Immune Phenotype and Best Overall Response to Atezolizumab + Cobimetinib PD-L1 (%) PDAC (2L) NSCLC (2L/3L post CPI/plat chemo) TC IC Longest Diameter From Baseline Longest Diameter From Baseline <1 <1 Best % Change in Sum of Best % Change in Sum of 100 100 1-

  7. Slide 7: Safety Summary

    Safety Summary PDAC (2L) PDAC (3L) NSCLC (2L/3L post CPI/plat chemo) GC (1L) CCODOct CCOD Oct14, 14,2020 2019 CCODOct CCOD Oct14, 14,2020 2019 CCOD FebFeb CCOD 14, 2020 14, 2020 CCODCCOD July 11,xxx 2019 n, (%) Controla Atezo + Cobi Atezo + Cobi Controlb Atezo + Cobi Atezo + mFOLFOX6 + (n = 15) (n =

  8. Slide 8: Conclusions

    Conclusions  MORPHEUS is an innovative adaptable platform that allowed rapid evaluation of atezolizumab + cobimetinib in multiple tumor types  PDAC − Although no responses were seen with 2L atezolizumab + cobimetinib (DCR was 0% vs 33% in control arm), 3L atezolizumab + cobimetinib led to a DCR of

Roche Holding — AACR 2020 on 6ix